Navigation Links
Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
Date:7/22/2011

CHAPEL HILL, N.C., July 22, 2011 /PRNewswire/ -- The structure of a biopharmaceutical company's Internal Communications group must evolve to reflect the changing goals and strategies. Realigning to support new corporate initiatives and establishing service levels to reflect priorities and resources are key improvement areas for Internal Communications executives in 2012.

"Differentiated services hold great value during times of resource reductions," according to "Internal Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC.

Download a complimentary white paper at http://www3.best-in-class.com/rr1094.htm that includes selected best practices drawn from extensive primary research with executives from 26 leading biopharmaceutical and medical device companies. The full 61-page report contains more than 100 benchmark metrics and 20 executive narratives, providing communications executives with organizational models and trends and insights about structure, staffing and investment levels.

Key insights include:

  • In the Pharma Segment, 52 percent of Internal Communications executives noted their group has a business unit focus while 48 percent have an enterprise-wide focus. Only 14 percent noted a product focus for the Internal Communications group.
  • While a majority of both biopharma and other industries favor a centralized approach for Internal Communications, a third of both takes a regional approach, where staff are placed in major regional offices (although a central group still resides at headquarters).

In conjunction with this study, "External Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC, addresses current trends in external communications with respect to its structural models, staffing and investment levels. A complimentary except is available at http://www3.best-in-class.com/rr1095.htm.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.  

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, ... to their offering. ... , The western blotting market ... 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
(Date:12/5/2016)... 5, 2016   BIOTRONIK today announced the ... study evaluates the safety and feasibility of performing the ... setting. BioMonitor 2 is an insertable cardiac ... placed underneath a patient,s skin to help physicians accurately ... fibrillation is a leading cause of stroke and heart ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... its latest transitional care facility – Avamere Transitional Care of Puget Sound ... foot short-term, post-acute health care center will provide patients recovering from illness or ...
(Date:12/5/2016)... St. Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... effects concussions have on the growing brains of young athletes. Over the course of ... to the head through unique mouth guards. The mouth guards, equipped with special sensors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):